Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1
复制标题
DOI：
10.1086/517614
复制
发表时间：
2007-06-01
影响因子：
6.4
通讯作者：
Rimmelzwaan, Guus F.
中科院分区：
文献类型：
--
作者：
Kreijtz, Joost H. C. M.;Suezer, Yasemin;Rimmelzwaan, Guus F.
自2003年以来，人类感染H5 N1亚型高致病性禽流感病毒的病例仍在增加，因此，开发安全有效的疫苗被视为优先事项。然而，全球常规疫苗的生产能力有限，不足以开展全球疫苗接种运动。在本研究中，一个替代的H5 N1疫苗候选人的基础上，复制缺陷型改良安卡拉牛痘病毒（MVA）进行了评估。用表达来自流感病毒A/Hongkong/156/97（MVAHAHK/ 97）或A/Vietnam/ 1194/04（MVA-HA-VN/ 04）的血凝素（HA）基因的MVA免疫C57 BL/6 J小鼠两次。随后，在用3种抗原性不同的H5 N1流感病毒株：A/Hongkong/156/97、A/Vietnam/1194/04和A/Indonesia/5/05攻击感染后评估重组MVA诱导的保护性免疫。我们的数据表明，表达流感病毒A/Vietnam/1194/04 HA的重组MVA是一种有前途的替代疫苗候选物，可用于诱导针对各种H5 N1流感病毒株的保护性免疫。
Since 2003, the number of human cases of infections with highly pathogenic avian influenza viruses of the H5N1 subtype is still increasing, and, therefore, the development of safe and effective vaccines is considered a priority. However, the global production capacity of conventional vaccines is limited and insufficient for a worldwide vaccination campaign. In the present study, an alternative H5N1 vaccine candidate based on the replication-deficient modified vaccinia virus Ankara (MVA) was evaluated. C57BL/6J mice were immunized twice with MVA expressing the hemagglutinin (HA) gene from influenza virus A/Hongkong/156/97 (MVAHAHK/ 97) or A/Vietnam/ 1194/04 (MVA-HA-VN/ 04). Subsequently, recombinant MVA-induced protective immunity was assessed after challenge infection with 3 antigenically distinct strains of H5N1 influenza viruses: A/Hongkong/156/97, A/Vietnam/1194/04, and A/Indonesia/5/05. Our data suggest that recombinant MVA expressing the HA of influenza virus A/Vietnam/1194/04 is a promising alternative vaccine candidate that could be used for the induction of protective immunity against various H5N1 influenza strains.